Literature DB >> 35037179

Routine Radiologic Assessment for Anastomotic Leak Is Not Necessary in Asymptomatic Patients After Esophagectomy for Esophageal Cancer.

Hansol Kang1, Kfir Ben-David2, George A Sarosi3,4, Ryan M Thomas5,6.   

Abstract

BACKGROUND: Anastomotic leaks (AL) are a major source of post-esophagectomy morbidity and patients are often initially asymptomatic. Debate exists on timing and utility of imaging to detect AL post-esophagectomy. We sought to evaluate the efficacy and timing of radiographic AL evaluation in esophageal cancer patients post-esophagectomy.
METHODS: A retrospective database of esophageal cancer patients who underwent esophagectomy at a single institution from 2004 to 2020 was used to determine the utilization, timing, and sensitivity of radiologic testing for AL post-esophagectomy.
RESULTS: Seventy-six patients were identified of which 37 (49%) had a cervical anastomosis. Sixty-four (84%) underwent 71 "asymptomatic radiographic leak tests" (ARLT), 7 of which had 2 different tests, including: 41 fluoroscopic esophagrams (58%), 18 CT-esophagrams (25%), and 12 upper GI studies (17%). Seventeen patients (22%) developed clinical signs of AL (hemodynamic instability, leukocytosis) and underwent "symptomatic radiographic leak tests" (SRLT) with fluoroscopic esophagram (n = 9, 12%), CT-esophagram (n = 7, 9%), or upper GI study (n = 1, 1%). ARLT and SRLT were positive in 2/64 (3%) and 17/17 (100%) patients, respectively, for 19 total ALs (25%). Among the 17 SRLT( +) patients, 1 was also ARLT( +), 13 were initially ARLT( -), and 3 were not evaluated by ARLT. The median postoperative day for ARLT and SRLT was 4.0 (IQR 3.0-5.5) and 9.0 days (IQR 6.0-13.0), respectively, with a statistically significant difference (p < 0.005). The sensitivity and specificity of ARLT for detecting AL were 13.3% and 100.0%, respectively.
CONCLUSIONS: Based on the low ARLT sensitivity, routine use of imaging to detect asymptomatic ALs post-esophagectomy may be limited. Symptomatic ALs were often present in a delayed fashion, even after initial negative imaging.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  Anastomotic leak; Esophageal cancer; Esophagectomy; Esophagram

Mesh:

Year:  2022        PMID: 35037179     DOI: 10.1007/s11605-021-05219-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  20 in total

1.  Routine contrast esophagram has minimal impact on the postoperative management of patients undergoing esophagectomy for esophageal cancer.

Authors:  Jonathan Cools-Lartigue; Amin Andalib; Ali Abo-Alsaud; Stephen Gowing; Maxime Nguyen; David Mulder; Lorenzo Ferri
Journal:  Ann Surg Oncol       Date:  2014-03-28       Impact factor: 5.344

2.  Intrathoracic leaks following esophagectomy are no longer associated with increased mortality.

Authors:  Linda W Martin; Stephen G Swisher; Wayne Hofstetter; Arlene M Correa; Reza J Mehran; David C Rice; Ara A Vaporciyan; Garrett L Walsh; Jack A Roth
Journal:  Ann Surg       Date:  2005-09       Impact factor: 12.969

Review 3.  Should routine radiological assessment of anastomotic integrity be performed after oesophagectomy with cervical anastomosis? Best evidence topic (BET).

Authors:  Christopher M Jones; Rebecca Heah; Brigette Clarke; Ewen A Griffiths
Journal:  Int J Surg       Date:  2015-02-07       Impact factor: 6.071

Review 4.  Should routine assessment of anastomotic integrity be undertaken using radiological contrast swallow after oesophagectomy with intra-thoracic anastomosis? Best evidence topic (BET).

Authors:  Christopher M Jones; Brigette Clarke; Rebecca Heah; Ewen A Griffiths
Journal:  Int J Surg       Date:  2015-07-10       Impact factor: 6.071

5.  The cost burden of clinically significant esophageal anastomotic leaks-a steep price to pay.

Authors:  John Agzarian; Sue L Visscher; Ariel W Knight; Mark S Allen; Stephen D Cassivi; Francis C Nichols; K Robert Shen; Dennis Wigle; Shanda H Blackmon
Journal:  J Thorac Cardiovasc Surg       Date:  2018-11-15       Impact factor: 5.209

6.  An evaluation of the routine use of contrast radiography as a screening test for cervical anastomotic integrity after esophagectomy.

Authors:  Daniel G Solomon; Clarence T Sasaki; Ronald R Salem
Journal:  Am J Surg       Date:  2011-09-09       Impact factor: 2.565

7.  The Diagnostic Value of Routine Contrast Esophagram in Anastomotic Leaks After Esophagectomy.

Authors:  Zhongwu Hu; Xiaowe Wang; Xush An; Wenjin Li; Yun Feng; Zhenbing You
Journal:  World J Surg       Date:  2017-08       Impact factor: 3.352

8.  Gastric interposition following transhiatal esophagectomy: radiographic evaluation.

Authors:  F P Agha; M B Orringer; M A Amendola
Journal:  Gastrointest Radiol       Date:  1985

9.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.

Authors:  Joel Shapiro; J Jan B van Lanschot; Maarten C C M Hulshof; Pieter van Hagen; Mark I van Berge Henegouwen; Bas P L Wijnhoven; Hanneke W M van Laarhoven; Grard A P Nieuwenhuijzen; Geke A P Hospers; Johannes J Bonenkamp; Miguel A Cuesta; Reinoud J B Blaisse; Olivier R C Busch; Fiebo J W Ten Kate; Geert-Jan M Creemers; Cornelis J A Punt; John Th M Plukker; Henk M W Verheul; Ernst J Spillenaar Bilgen; Herman van Dekken; Maurice J C van der Sangen; Tom Rozema; Katharina Biermann; Jannet C Beukema; Anna H M Piet; Caroline M van Rij; Janny G Reinders; Hugo W Tilanus; Ewout W Steyerberg; Ate van der Gaast
Journal:  Lancet Oncol       Date:  2015-08-05       Impact factor: 41.316

10.  Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.

Authors:  Joel Tepper; Mark J Krasna; Donna Niedzwiecki; Donna Hollis; Carolyn E Reed; Richard Goldberg; Krystyna Kiel; Christopher Willett; David Sugarbaker; Robert Mayer
Journal:  J Clin Oncol       Date:  2008-03-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.